In brief: KabaFusion expands footprint, CGM reduces hospitalizations, Apnimed shares positive results 

LEXINGTON, Mass. – KabaFusion has closed on the acquisition of six locations from Coram that will serve as pharmacies and ambulatory infusion suites.   

The transaction will expand KabaFusion’s ability to serve a growing number of patients nationwide and strengthen its commitment to deliver high-quality patient care across a broad range of therapies, the company says. 

“Our expansion will enable KabaFusion to serve a greater number of patients with superior care,” said Dr. Sohail Masood, founder and CEO of KabaFusion. “Patient demand for home and ambulatory infusion services continues to increase, and we are thrilled to open new locations to meet the needs of our patients. We will continue to partner with practitioners, physicians, manufacturers and payers to provide superior infusion services with clinical excellence.” 

This acquisition will expand KabaFusion’s footprint to 32 infusion pharmacies and 19 ambulatory infusion suites, allowing the company to enter new strategic markets in Connecticut, Georgia, Oklahoma, South Carolina and Washington, and expand its existing footprint in Nevada. 

KabaFusion, which is licensed to serve patients in 45 states, is a portfolio company of Novo Holdings. 

Terms of the transaction were not disclosed. 

• Related: KabaFusion partners with Memorial Hermann Health System and leverages Innovalon software. 

Studies link Abbott CGM with reduced hospitalizations 

ABBOTT PARK, Ill. – Abbott’s FreeStyle Libre continuous glucose monitoring technology is associated with a significant reduction in the risk of hospitalization for heart complications in people with diabetes, according to the results of the company’s REFLECT real-world studies. 

For the first time, Abbott says, data show that CGM technology can help lessen the severity of cardiovascular complications – regardless of a prior history of low blood sugar events or heart disease-related hospitalizations – in individuals with Type 1 diabetes. Data also show a similar reduction in heart-related hospitalizations for those with Type 2 diabetes on insulin using Libre biowearable technology, the company says. 

"These results are remarkable, as we see dual benefits from CGM technology in managing diabetes and its associated cardiovascular complications," said David Nathanson, MD, PhD, Karolinska University Hospital in Sweden, one of the lead authors of the studies. "CGMs empower people to proactively manage their diabetes and make informed health choices through real-time, constant feedback on their glucose levels. This data shows that using CGMs is linked with significantly reduced hospitalizations related to heart issues, which can have a significant impact on patients, their families and the health care system by easing medical, emotional and financial burdens." 

The data also reveal that the risk of hospitalizations for cardiovascular disease was reduced by 80% among people with Type 1 diabetes with no prior history of cardiovascular disease when using the Libre biowearable technology compared to those who used a traditional blood glucose monitor. For individuals with a prior history of cardiovascular disease, the risk of hospitalizations was reduced by 49%. 

The REFLECT studies, funded by Abbott, were real-world retrospective studies conducted using data from the Swedish National Diabetes Register (NDR), one of the largest and most comprehensive diabetes registers in the world representing approximately 90% of all patients with diabetes in Sweden. 

The REFLECT research considered a range of cardiovascular-disease related conditions including non-fatal heart attack, non-fatal stroke, coronary artery disease, heart failure, atrial fibrillation and cardiovascular death – conditions commonly seen in people with diabetes.7 

"I regularly treat people with diabetes who have problems with their blood vessels, resulting in heart attacks, strokes and amputations," said Ramzi Ajjan, M.D., professor of Metabolic Medicine at University of Leeds and Leeds Teaching Hospitals NHS Trust. "These blood vessel problems, known collectively as cardiovascular disease, remain the main causes of ill health and death in people with diabetes. I am very excited to see data that show significant reduction in cardiovascular disease-related hospital admissions. It's great to see the clear, positive impact of FreeStyle Libre technology on cardiovascular outcomes, making diabetes management more effective and improving the health of our patients." 

The studies, published between October 2024 and April 2025, assessed: 

1. The impact of intermittently scanned CGM versus blood glucose monitoring on HbA1c levels and hospitalizations in adults with insulin-treated Type 2 diabetes; 
2. The impact of intermittently scanned CGM versus blood glucose monitoring on hospitalization rates for metabolic and vascular complications and HbA1c levels for adults with Type 1 diabetes; and 
3. The risk of cardiovascular complications after severe hypoglycemia in adults with Type 1 diabetes, and the risk of post-severe hypoglycemia cardiovascular complications for intermittently scanned CGM users versus blood glucose monitoring users. 

EnsoData adds position data to sleep test 

MADISON, Wis. – The FDA-cleared EnsoSleep PPG home sleep test now features position data captured by Advanced Brain Monitoring’s Night Shift sleep positioner. Incorporating positional data provides a more complete diagnostic picture of the patient’s sleep: 21% of sleep apnea patients would have little-to-no breathing problems if back-sleeping were avoided, and 70% of patients diagnosed with OSA are substantially more severe when back-sleeping, according to ABM research. “The integration is designed to help recognize more patients who may have a positional component contributing to the severity of their sleep-disordered breathing,” said Daniel J. Levendowski, president, Advanced Brain Monitoring. “This improvement in the HSAT could result in a more personalized approach for first-line OSA therapy recommendations and/or improved selection of alternative therapies for patients who fail to adapt to CPAP.” The FDA-cleared Night Shift records positional data that will be displayed in EnsoSleep PPG Study Management and can be added to dynamic patient reports. Incorporating more data through multi-night, multi-sensor testing will provide a more comprehensive understanding of overall sleep issues across the patient population, allowing providers to better diagnose conditions like positional sleep apnea, according to EnsoData. “When one in five patients suffering from OSA can be treated with simple body position adjustment therapy, it’s time to address that patient population head on,” said Brock Hensen, COO, EnsoData. “By adding sleep position data provided by Advanced Brain Monitoring’s Night Shift, we can instill physician confidence in new home sleep testing modalities that provide accurate diagnostic data in simple, affordable form factors to replace aging legacy devices.” 

Ottobock.care opens gym for advanced prosthetic users 

DALLAS – Ottobock.care, the clinical care division of Ottobock, has opened a new, state-of-the-art gym space designed specifically for high-performing athletes at its Scott Sabolich Ottobock.care clinic in Texas. Unlike traditional physical therapy gyms, the space features specialized equipment—including treadmills, stationary bikes and rowing machines—chosen for safety and suitability for advanced prosthetic users. "We wanted to create an environment where our patients don't just recover—they train, grow and push boundaries," said Corey Dennis, MSOP CPO LP, chief prosthetist and regional clinic manager at Scott Sabolich Ottobock.care. "This gym is a natural extension of our philosophy: It's a place where progress is shared, strength is built together and active life moves forward." The new space, which was built into the existing clinic through a full-scale remodel, adds to the legacy of Scott Sabolich, a name synonymous with innovation and excellence in prosthetic care. Founded in Oklahoma City and now serving patients in Texas, Scott Sabolich Ottobock.care clinics are known for treating some of the most complex cases in the country, with people traveling from across the U.S. to access the team's decades of experience, personalized care and commitment to finding the right solution. The space is available to all prosthetic patients. 

Henry Schein completes investment, names new board members 

MELVILLE, N.Y. - Henry Schein has announced the completion of a $250 million strategic investment by funds affiliated with KKR, making the investment firm a holder of about 12% of the common shares of the company, and the appointment of William K. “Dan” Daniel as an independent director. Daniel is an executive advisor to KKR and a former executive vice president of Danaher Corp. He joins Max Lin, partner at KKR and leader of the firm’s health care industry team in the Americas, who became a member of Henry Schein’s board on May 2. “We are pleased to welcome Max and Dan to the Board as we embark on this exciting next chapter for Henry Schein,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. “Their deep experience in health care, operations, and strategic growth will be invaluable as we continue executing on our BOLD+1 strategy and creating long-term value for our stakeholders.” In connection with each of their appointments, Lin was appointed to the Nominating and Governance Committee as vice chair, and Daniel was appointed to the Compensation Committee. Both were appointed to the Strategic Advisory Committee. 

• Related: Henry Schein receives funding and advances bold plan. 

Apnimed shares positive results for sleep apnea pill 

CAMBRIDGE, Mass. - Apnimed has announced positive topline results from its pivotal Phase 3 SynAIRgy clinical trial evaluating the efficacy and safety of AD109 in adults living with mid, moderate and severe OSA and across all weight classes. The SynAIRgy trial met its primary endpoint: mean change from baseline in the apnea-hypopnea index (AHI) at 26 weeks compared to placebo (p=0.001). “Today is a landmark moment for Apnimed and for millions living with OSA who have long struggled with limited treatment options,” said Larry Miller, MD, CEO of Apnimed. “The positive results from our Phase 3 SynAIRgy trial bring us closer to realizing our vision of offering a simple, safe and effective oral drug — one that is grounded in science, driven by unmet need, and centered on people with OSA. We believe these results represent the dawn of a new era in the OSA treatment paradigm.” Apnimed  plans to submit a New Drug Application for AD109 to the U.S. Food and Drug Administration by early 2026 for regulatory review. The company also anticipates the availability of topline data in Q3 2025 from the second Phase 3 LunAIRo trial, a one-year study of AD109 in adults with OSA. AD109 is designed to be the first pharmacological treatment to improve oxygenation during sleep by directly addressing the neuromuscular root cause of upper airway collapse in people with OSA. It is a combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor (NRI). Apnimed says AD109, which is a once-daily pill taken at bedtime, is designed to lower the complexity of intervention and may help more people benefit from effective, restorative sleep. 

Philips executes offering 

AMSTERDAM – Royal Philips has announced the successful pricing of its offering of EUR 500 million fixed rate notes due 2030 and EUR 500 million fixed rate notes due 2035 under its European Medium Term Note program. The net proceeds will be used for general corporate purposes, the repayment of 2026 debt maturities and to refinance or finance any eligible projects as defined in Philips’ Sustainable Finance Framework. The issue price for the notes due 2030 is 99.859% with a coupon of 3.25%, resulting in a yield of 3.281% and the issue price for the notes due 2035 is 99.595% with a coupon of 4%, resulting in a yield of 4.05%. The 5- and 10-year tranches were oversubscribed by more than three and four times, respectively. Settlement and issue of the notes is scheduled for May 23, 2025.  

Kia launches WAV model 

SEOUL – Kia Corp. showcased the PV5 Wheelchair Accessible Vehicle model, a collaboration with the U.K.-based Motability Solutions Provider, at the Financial Times’ Future of the Car Summit in London. Part of Kia's ongoing commitment and contribution to enhancing mobility for people with disabilities, its presence at the Summit underscores the company’s leadership as a Sustainable Mobility Solutions Provider, it says. "The PV5 WAV is more than just a vehicle; it's a gateway to independence and freedom for those with mobility challenges,” said Sangdae Kim, executive vice president and head of PBV Division at Kia. “By integrating cutting-edge Platform Beyond Vehicle (PBV) technology with thoughtful design, we are paving the way for a future where everyone can enjoy the benefits of sustainable mobility, and our partnership with Motability Operations is a testament to our commitment to making this vision a reality." The PV5 WAV features a side-entry system that allows wheelchair users to board safely from the sidewalk. It also includes a third-row tip-up seat, enabling caregivers to assist wheelchair passengers from the side. Kia previously announced its collaboration with Motability Operations, a long-term partner in the Motability Scheme, which allows users receiving a qualifying disability allowance to choose an affordable and accessible vehicle. Motability is the largest vehicle leasing company in the U.K. 

Resmed sponsors rugby tour 

SAN DIEGO – Resmed has been named the Official Sleep Partner of the Qatar Airways British & Irish Lions Tour to Australia. For the first time in 12 years, the Lions squad, alongside an estimated 40,000 fans, will battle it out with the Wallabies, Super Rugby Pacific teams and exhibition sides in six cities across Australia. As the Official Sleep Partner, Resmed will launch “Tackle Your Sleep,” a digital and content focused campaign featuring legendary rugby players that aims to raise awareness about the importance of quality sleep, alongside exercise and diet. “Poor sleep affects every aspect of our lives, but the good news is there are steps we can take to improve our sleep health,” said Katrin Pucknat, chief marketing officer of Resmed. “As the Official Sleep Partner of the tour, we’re excited to raise awareness about the powerful connection between sleep and athletic performance and inspire fans to think about the role that sleep plays in their own lives, while having some fun along the way.” The British & Irish Lions will play 10 matches in total, with three test matches against the Wallabies in Brisbane, Melbourne and Sydney. 

John Miclot passes away 

PITTSBURGH – John Miclot, who spent 10 years at Respironics, including as president and CEO from 2003-08, has passed way. After his tenure at Respironics, he became an executive in residence at Warburg Pincus, served as CEO of CCS Medical and CEO of LinguaFlex, and lead Tengion. During his career, Miclot also held executive positions at Healthdyne Technologies, Medex, Ohmeda, Baxter Edwards and DeRoyal Industries. He was 66.